48/120
2.0 / 5 stars
All 120 Win/Lose results shown below
BCRX Roast Me summary
BIOCRYST PHARMACEUTICALS INC (BCRX). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth Lose.
Trailing 1 year (4 quarters): 6 wins, 6 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseBCRX / S&P 5.04% / 15.20% |
WinBCRX / S&P 68.72% / 15.00% |
LoseBCRX / S&P BCRX unavailable / 50.40% |
| 2026-Q12/3 |
WinBCRX / S&P 22.05% / -4.33% |
WinBCRX / S&P 75.92% / 11.30% |
LoseBCRX / S&P BCRX unavailable / 27.70% |
| 2025-Q42/3 |
WinBCRX / S&P 2.77% / 2.65% |
WinBCRX / S&P 94.10% / 9.00% |
LoseBCRX / S&P BCRX unavailable / 13.40% |
| 2025-Q31/3 |
LoseBCRX / S&P -15.29% / 8.12% |
WinBCRX / S&P 45.38% / 4.61% |
LoseBCRX / S&P BCRX unavailable / 13.45% |
| 2025-Q22/3 |
WinBCRX / S&P 19.47% / 10.94% |
WinBCRX / S&P 45.85% / 4.83% |
LoseBCRX / S&P BCRX unavailable / 10.63% |
| 2025-Q12/3 |
WinBCRX / S&P -0.27% / -4.27% |
WinBCRX / S&P 41.67% / 4.98% |
LoseBCRX / S&P BCRX unavailable / 10.57% |
| 2024-Q41/3 |
LoseBCRX / S&P -1.05% / 2.41% |
WinBCRX / S&P 36.00% / 5.25% |
LoseBCRX / S&P BCRX unavailable / 6.15% |
| 2024-Q32/3 |
WinBCRX / S&P 22.98% / 5.89% |
WinBCRX / S&P 29.92% / 5.89% |
LoseBCRX / S&P BCRX unavailable / 6.11% |
| 2024-Q22/3 |
WinBCRX / S&P 21.65% / 4.28% |
WinBCRX / S&P 24.65% / 5.38% |
LoseBCRX / S&P BCRX unavailable / 5.12% |
| 2024-Q11/3 |
LoseBCRX / S&P -15.19% / 10.56% |
WinBCRX / S&P 22.68% / 5.71% |
LoseBCRX / S&P BCRX unavailable / 5.59% |
| 2023-Q41/3 |
LoseBCRX / S&P -15.40% / 11.69% |
WinBCRX / S&P 22.37% / 6.81% |
LoseBCRX / S&P BCRX unavailable / 7.78% |
| 2023-Q32/3 |
WinBCRX / S&P 0.57% / -3.27% |
WinBCRX / S&P 33.18% / 7.52% |
LoseBCRX / S&P BCRX unavailable / -5.03% |
| 2023-Q21/3 |
LoseBCRX / S&P -15.59% / 8.74% |
WinBCRX / S&P 50.60% / 9.50% |
LoseBCRX / S&P BCRX unavailable / -8.57% |
| 2023-Q11/3 |
LoseBCRX / S&P -27.35% / 7.50% |
WinBCRX / S&P 54.06% / 10.77% |
LoseBCRX / S&P BCRX unavailable / -15.69% |
| 2022-Q41/3 |
LoseBCRX / S&P -8.89% / 7.56% |
WinBCRX / S&P 72.31% / 11.88% |
LoseBCRX / S&P BCRX unavailable / -17.99% |
| 2022-Q32/3 |
WinBCRX / S&P 19.09% / -4.88% |
WinBCRX / S&P 109.11% / 13.47% |
LoseBCRX / S&P BCRX unavailable / -1.41% |
| 2022-Q21/3 |
LoseBCRX / S&P -34.93% / -16.10% |
WinBCRX / S&P 157.29% / 13.71% |
LoseBCRX / S&P BCRX unavailable / 11.04% |
| 2022-Q12/3 |
WinBCRX / S&P 17.40% / -4.60% |
WinBCRX / S&P 486.73% / 15.97% |
LoseBCRX / S&P BCRX unavailable / 42.23% |
| 2021-Q41/3 |
LoseBCRX / S&P -3.62% / 11.03% |
WinBCRX / S&P 782.38% / 15.00% |
LoseBCRX / S&P BCRX unavailable / 96.40% |
| 2021-Q31/3 |
LoseBCRX / S&P -9.11% / 0.58% |
WinBCRX / S&P 113.05% / 10.77% |
LoseBCRX / S&P BCRX unavailable / 69.42% |
| 2021-Q22/3 |
WinBCRX / S&P 55.46% / 8.55% |
WinBCRX / S&P 60.87% / 6.58% |
LoseBCRX / S&P BCRX unavailable / 51.81% |
| 2021-Q11/3 |
WinBCRX / S&P 36.51% / 6.17% |
LoseBCRX / S&P -32.91% / -1.06% |
LoseBCRX / S&P BCRX unavailable / 7.39% |
| 2020-Q41/3 |
WinBCRX / S&P 116.57% / 12.15% |
LoseBCRX / S&P -63.53% / -3.72% |
LoseBCRX / S&P BCRX unavailable / -33.42% |
| 2020-Q31/3 |
LoseBCRX / S&P -27.73% / 8.93% |
WinBCRX / S&P 352.07% / -2.04% |
LoseBCRX / S&P BCRX unavailable / -27.10% |
| 2020-Q22/3 |
WinBCRX / S&P 138.00% / 20.54% |
WinBCRX / S&P 327.11% / -0.46% |
LoseBCRX / S&P BCRX unavailable / -27.11% |
| 2020-Q11/3 |
LoseBCRX / S&P -42.03% / -19.60% |
WinBCRX / S&P 111.71% / 3.47% |
LoseBCRX / S&P BCRX unavailable / -14.75% |
| 2019-Q42/3 |
WinBCRX / S&P 20.21% / 9.07% |
WinBCRX / S&P 136.45% / 5.36% |
LoseBCRX / S&P BCRX unavailable / 2.99% |
| 2019-Q30/3 |
LoseBCRX / S&P -24.27% / 1.70% |
LoseBCRX / S&P -45.73% / 5.02% |
LoseBCRX / S&P BCRX unavailable / 0.21% |
| 2019-Q20/3 |
LoseBCRX / S&P -53.44% / 4.30% |
LoseBCRX / S&P -60.45% / 6.64% |
LoseBCRX / S&P BCRX unavailable / 8.65% |
| 2019-Q11/3 |
LoseBCRX / S&P 0.87% / 13.65% |
WinBCRX / S&P 14.39% / 8.12% |
LoseBCRX / S&P BCRX unavailable / 14.29% |
| 2018-Q41/3 |
WinBCRX / S&P 5.77% / -13.52% |
LoseBCRX / S&P -18.00% / 9.05% |
LoseBCRX / S&P BCRX unavailable / 18.23% |
| 2018-Q31/3 |
WinBCRX / S&P 33.16% / 7.71% |
LoseBCRX / S&P -27.96% / 10.21% |
LoseBCRX / S&P BCRX unavailable / 19.06% |
| 2018-Q21/3 |
WinBCRX / S&P 20.13% / 3.43% |
LoseBCRX / S&P -0.55% / 9.03% |
LoseBCRX / S&P BCRX unavailable / 14.46% |
| 2018-Q10/3 |
LoseBCRX / S&P -2.85% / -0.76% |
LoseBCRX / S&P -36.31% / 7.68% |
LoseBCRX / S&P BCRX unavailable / 12.46% |
| 2017-Q40/3 |
LoseBCRX / S&P -6.30% / 6.64% |
LoseBCRX / S&P -4.43% / 7.03% |
LoseBCRX / S&P BCRX unavailable / 13.82% |
| 2017-Q31/3 |
LoseBCRX / S&P -5.76% / 4.48% |
WinBCRX / S&P 37.81% / 5.68% |
LoseBCRX / S&P BCRX unavailable / 17.57% |
| 2017-Q21/3 |
LoseBCRX / S&P -33.81% / 3.09% |
WinBCRX / S&P 16.22% / 4.83% |
LoseBCRX / S&P BCRX unavailable / 17.74% |
| 2017-Q11/3 |
WinBCRX / S&P 32.70% / 6.07% |
LoseBCRX / S&P -33.04% / 3.67% |
LoseBCRX / S&P BCRX unavailable / 13.32% |
| 2016-Q41/3 |
WinBCRX / S&P 43.54% / 3.82% |
LoseBCRX / S&P -45.39% / 2.09% |
LoseBCRX / S&P BCRX unavailable / 7.05% |
| 2016-Q31/3 |
WinBCRX / S&P 55.28% / 3.85% |
LoseBCRX / S&P -55.25% / 0.20% |
LoseBCRX / S&P BCRX unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | BCRX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 18.29% | 20.78% |
| Annualized return | 18.29% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | BCRX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -39.13% | 83.14% |
| Annualized return | -9.45% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | BCRX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 136.30% | 319.30% |
| Annualized return | 8.98% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |